Publications for Lars Cöster
Co-author map based on ISI articles 2007-
Journal Articles
Alf Kastbom, Lars Cöster, Lisbeth Ärlestig, Aikaterini Chatzidionysiou, Ronald F. van Vollenhoven, Leonid Padyukov, Solbritt Rantapää-Dahlqvist and Saedis Saevarsdottir
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
BMJ Open, 2012, 2(5), .
Fulltext  Web of Science® Times Cited: 1 |
Julia F Simard, Elizabeth V Arkema, Tore Saxne, Eva Baecklund, Lars Cöster, Christina Dackhammar, Lennart Jacobsson, Nils Feltelius, Staffan Lindblad, Solbritt Rantapaa-Dahlqvist, Lars Klareskog, Ronald F van Vollenhoven and Martin Neovius
Ten years with biologics: to whom do data on effectiveness and safety apply?
RHEUMATOLOGY, 2011, 50(1), 204-213.
Web of Science® Times Cited: 7 |
Johan Askling, Ronald F van Vollenhoven, Fredrik Granath, Pauline Raaschou, C Michael Fored, Eva Baecklund, Christina Dackhammar, Nils Feltelius, Lars Cöster, Pierre Geborek, Lennart T Jacobsson, Staffan Lindblad, Solbritt Rantapaa-Dahlqvist, Tore Saxne and Lars Klareskog
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor alpha Therapies Does the Risk Change With the Time Since Start of Treatment?
ARTHRITIS AND RHEUMATISM, 2009, 60(11), 3180-3189.
Web of Science® Times Cited: 63 |
R.F. van Vollenhoven, S. Ernestam, P. Geborek, I.F. Petersson, Lars Cöster, E. Waltbrand, A. Zickert, J. Theander, A. Thorner, H. Hellstrom, A. Teleman, C. Dackhammar, F. Akre, K. Forslind, L. Ljung, R. Oding, A. Chatzidionysiou, M. Wornert and J. Bratt
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
The Lancet, 2009, 374(9688), 459-466.
Web of Science® Times Cited: 71 |
J Askling, E Baecklund, F Granath, P Geborek, M Fored, C Backlin, L Bertilsson, Lars Cöster, L T Jacobsson, S Lindblad, J Lysholm, S Rantapaa-Dahlqvist, T Saxne, R van Vollenhoven, L Klareskog and N Feltelius
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68(5), 648-653.
Web of Science® Times Cited: 74 |
Lars Cöster, Sally Kendall, Björn Gerdle, Chris Henriksson, Karl-Gösta Henriksson and Ann Bengtsson
Chronic widespread musculoskeletal pain - A comparison of those who meet criteria for fibromyalgia and those who do not
European Journal of Pain, 2008, 12(5), 600-610.
Web of Science® Times Cited: 35 |
Björn Gerdle, Jonas Björk, Lars Cöster, Karl-Gösta Henriksson, Chris Henriksson and Ann Bengtsson
Prevalence of widespread pain and associations with work status: A population study
BMC Musculoskeletal Disorders, 2008, 9, .
|
J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelius, Lars Cöster, P Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, RF van Vollenhoven and L Klareskog
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
Annals of the Rheumatic Diseases, 2007, 66(10), 1339-1344.
Web of Science® Times Cited: 97 |
Johan Askling, Michael Fored, Lena Brandt, Eva Baecklund, Lennart Bertilsson, Lars Cöster, Pierre Geborek, Lennart T Jacobsson, Staffan Lindblad, Jörgen Lysholm, Solbritt Rantapää-Dahlqvist, Tore Saxne, Victoria Romanus, Lars Klareskog and Nils Feltelius
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
Arthritis and Rheumatism, 2005, 52(7), 1986-1992.
Web of Science® Times Cited: 135 |
J Askling, CM Fored, E Baecklund, L Brandt, C Backlin, A Ekbom, C Sundström, L Bertilsson, Lars Cöster, P Geborek, Lt Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne, L Klareskog and N Feltelius
Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
Annals of the Rheumatic Diseases, 2005, 64(10), 1414-1420.
Web of Science® Times Cited: 179 |
J Askling, CM Fored, L Brandt, E Baecklund, L Bertilsson, N Feltelius, Lars Cöster, P Geborek, LT Jacobsson, S Lindblad, J Lysholm, S Rantapää-Dahlqvist, T Saxne and L Klareskog
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
Annals of the Rheumatic Diseases, 2005, 64(10), 1421-1426.
Web of Science® Times Cited: 154 |
Conference Articles
Ph.D., Lic. Theses
